Search This Blog

Friday, February 10, 2023

AstraZeneca: Jeremy Hunt 'disappointed' by drugs firm's low tax move

 Chancellor Jeremy Hunt has said he is "disappointed" drugs giant AstraZeneca has chosen the low-tax Republic of Ireland over the UK to build a new £320m factory.

The firm's chief executive said it had wanted to build the site in north-west England, but the "discouraging" tax rate meant it chose Dublin instead.

Mr Hunt said he agreed with the firm's "fundamental case" on business taxes.

But he said the government would not consider tax cuts funded by borrowing.


AstraZeneca already has sites close to Macclesfield, Cheshire, and had originally wanted to build its new factory nearby.

Mr Hunt told the BBC: "We're disappointed that we lost out this time. And we agree with the fundamental case they're making which is that we need our business taxation to be more competitive and we want to bring business taxes down.

"But the only tax cuts we won't consider are ones that are funded by borrowing because they're not a real tax cut. They're just passing on the bill to future generations."

He added: "If you look at life sciences, we have billion pound investments announced recently by BioNTech, by Moderna, by Merck, by other big pharmaceutical companies. We think we are in a tremendously strong position, with the biggest Life Science Centre in Europe.'


In April corporation tax, which is paid by UK companies and foreign firms with UK offices, is due to increase from 19% to 25%.

Dr Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry, said: "There are more stories about losing investment, like the one we've seen with AstraZeneca, than the positive noise stories coming in, and we really have to turn that around."

AstraZeneca and others in the sector have also expressed concern about the NHS-branded medicines sales levy, which has soared because of rising demand since the Covid pandemic.

Mr Torbett told BBC Radio 4's Today programme: "The agreement we have with the NHS, that has got to the point where companies are now paying more than a quarter of their revenues - not profit but revenues - back to the government.

"That is vastly in excess of anything the industry pays anywhere else in the world and we have to get to the point where the UK is able to compete for investment on a level playing field, and we are not there yet."

Conservative MP Sir John Redwood said the UK was "being undercut mercilessly by the Irish tax system".

Sir John is member of the Conservative Growth Group of backbench MPs, calling for a return to ex-PM Liz Truss's tax cutting agenda.

Mr Hunt has warned it is unlikely there will be any room for "significant" tax cuts in the Budget in March.

It comes as new figures show the UK narrowly avoided falling into recession in 2022, after the economy saw zero growth between October and December.

The Bank of England still expects the UK to enter recession this year - usually defined as when the economy shrinks for two consecutive three-moth periods.


https://www.bbc.com/news/uk-politics-64596743

Genentech’s Vabysmo Improved Retinal Vein Occlusionin Phase 3

 

  • Vabysmo met its primary endpoint in two clinical trials, BALATON and COMINO, showing non-inferior visual acuity gains compared to aflibercept
  • More Vabysmo patients showed an absence of blood vessel leakage in the retina compared to aflibercept in a pre-specified exploratory endpoint
  • If approved, RVO would be the third indication for Vabysmo in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema

GSK: Jemperli OKd for recurrent or advanced mismatch repair-deficient endometrial cancer

 

  • Conversion from accelerated to regular (full) approval based on long-term outcomes from the GARNET phase I trial, which demonstrated an overall response rate of 45.4%
  • 85.9% of patients had duration of response ≥12 months and 54.7% of patients had duration of response ≥24 months

Thursday, February 9, 2023

Applied DNA updates on development progress

 "We remain committed to our timeline to building a cGMP manufacturing facility by the end of the current calendar year but are pivoting to a cost-efficient footprint within our corporate headquarters that maintains our ability to produce cGMP-grade product for current and prospective customers to validate for use in clinical trials. We also plan to leverage our platform advantages in the coming months to offer industry-leading DNA-sequence-to-IVT-template turnaround times."

Concluded Dr. Hayward, "At ADCL, we believe we are well positioned to leverage the population health platform we built during the pandemic to propel this subsidiary into the genetic testing marketplace of the future. Approaching enterprise customers with a reference lab model differentiates ADCL from those labs struggling to gain reimbursement from third parties and insurance companies. We have successfully completed our clinical validation and data analysis for our pharmacogenomics (PGx) testing panel and plan to file our validation package with New York State Department of Health in the coming weeks. Prospective PGx customer feedback has been very encouraging and gives us confidence that PGx testing can be a profitable post-pandemic path forward. In our supply chain traceability business, we continued to add CertainT® platform customers for isotopic analysis testing, which is an excellent complement to DNA tagging. We are encouraged by the macro environment for textile material provenance testing following the recent passage of the federal Omnibus Bill that increases funding for compliance with the Uyghur Forced Labor Prevention Act."

https://finance.yahoo.com/news/applied-dna-reports-first-quarter-210500116.html

Chinese AI-Related Stocks Slump After State-Media Warning

 Chinese artificial-intelligence-related shares fell sharply Thursday, after a state-media outlet published a commentary on the risks associated with ChatGPT-concept stocks.

Hong-Kong listed Baidu Inc. dropped as much as 8.5% and was recently 5.8% lower at 148.30 Hong Kong dollars (US$18.89). The stock has risen 33% so far this year after the company this week confirmed that it is internally testing an AI chatbot, called Ernie Bot. Baidu said it expects to launch the product to the public in March.

Cloudwalk Technology Co. and Beijing Haitian Ruisheng Science Technology Ltd. in Shanghai fell as much as 14% and 13%, respectively, after the Securities Times newspaper warned of overheating ChatGPT-related stocks and the risks of chasing the concept hype in a front-page editorial. ?

The article said that "some market capitals are keen on false concept speculation, luring investors to chase the market, and finally end up with losing. Investors must not follow the trend."

Thursday's commentary by the state media came after several Chinese AI-related stocks skyrocketed, as investors bet on these companies to benefit from the technology and its commercialization.

Shares of Cloudwalk, a face-recognition system developer, have doubled this year, while those of AI-related data provider Beijing Haitian Ruisheng have tripled over the same period.

Both companies have received a supervision letter from the Shanghai Stock Exchange and are required to respond with regard to their disclosure obligations.

Beijing Haitian Ruisheng said in a Thursday filing that it is a data provider to AI companies and doesn't engage in AI algorithm and application development.

In a sign of how competitive the global AI race has become, Google's Bard AI chatbot offered a wrong answer in an advertisement designed to show off the new tech, sending shares in parent company Alphabet Inc. 7.7% lower Wednesday.

https://www.marketscreener.com/quote/stock/BAIDU-INC-8563/news/Chinese-AI-Related-Stocks-Slump-After-State-Media-Warning-42936838/

Pence group launching grassroots Iowa effort targeting school transgender policies

 Former Vice President Mike Pence’s political advocacy group is launching a round of ads in Iowa pushing back against transgender-affirming policies in schools, Pence’s latest outreach in the early voting state as he mulls a 2024 presidential bid.

Advancing American Freedom, a group formed in 2021 by Pence to promote his agenda, announced Thursday a “grassroots campaign” focused on parents’ rights.

“The strength of our nation is tied to the strength of our families, and we cannot stand idly by as the Radical Left attempts to indoctrinate our children behind parents’ backs,” Pence said in a statement. “Advancing American Freedom will not rest until parental rights are restored in Iowa and across the nation.”

Specifically, the advertisements, rallies and events will focus on a policy adopted last year by a district near Cedar Rapids, Iowa, allowing transgender students to request a support plan to help them socially transition at school, with or without their parents’ permission.

Pence is supporting a group of parents who are suing the Linn-Mar Community School District to overturn the policy. Arguments in the case are set to begin on Wednesday in federal court in Minnesota.

Parents’ rights and the pushback against gender-affirming policies for transgender youth have been particularly animating issues for conservatives, with state legislatures introducing and passing bills aiming to block the discussion of gender identity in schools or the approval of gender-affirming care for those who are transitioning, and targeting transgender athletes in schools.

The Dispatch first reported that Pence also plans to visit Iowa next week to mark the start of the grassroots campaign, a trip that will coincide with former Ambassador to the United Nations Nikki Haley’s own 2024 presidential campaign launch.

Pence has said he is considering whether to run for president in 2024 or serve as a voice for conservative issues without running for elected office. He told The Hill in an interview last month he would discuss the matter with his family and supporters in the coming months before officially deciding.

Pence has said on multiple occasions he believes Americans are looking for new leadership, underscoring his desire for the party to move on from former President Trump, who is the only declared candidate in the race.

The ad buy is Pence’s latest foray into Iowa, which will hold the first caucus in the GOP 2024 primary in roughly one year. The former vice president has visited the state for party events and met with evangelical leaders, and his advocacy group has aired ads focused on energy policy.

https://thehill.com/homenews/campaign/3851205-pence-group-launching-grassroots-iowa-effort-targeting-school-transgender-policies/

CDC adds COVID vaccine to routine immunization schedule for kids, adults

 COVID-19 vaccines are now included among the routine shots recommended by the Centers for Disease Control and Prevention (CDC) for children, adolescents and adults.

The 2023 list includes shots for the flu, measles mumps and rubella, polio, and other inoculations.The vaccine schedule represents the current recommendations for people as a regular part of their vaccinations against common infectious diseases. It does not mean the CDC is requiring a COVID-19 shot for children or that schools will have to require that students receive the shot before enrolling.

The vaccine schedule is an important resource for physicians, especially pediatricians, that can help guide them on when it’s best to administer certain vaccines. 

The CDC does not have the authority to mandate vaccines; that decision is left up to states and local jurisdictions.

For example, the flu vaccine has long been on the schedule of recommended childhood immunizations, but hardly any state actually mandates it for public schools.

Under the new guidelines, healthy children 6 months to 4 years old should receive a primary series of two doses of either the Moderna or Pfizer-BioNTech monovalent COVID-19 vaccine followed by a third dose of a bivalent vaccine.

Children 5 to 11 years old should receive two doses of the Moderna or Pfizer-BioNTech vaccine followed by a bivalent shot.

Children 12 years and older should get either two doses of the Moderna, Pfizer or Novavax vaccine followed by a bivalent booster

Nearly 85 percent of adults in the U.S. have completed their primary COVID-19 vaccination series, according to the CDC, but only about a third have received a bivalent booster.

The recommendations were first made by a CDC advisory panel in October. Panel members at the time said that since the coronavirus is not going away, it makes sense to recommend children get vaccinated. 

https://thehill.com/policy/healthcare/3851977-cdc-adds-covid-vaccine-to-routine-immunization-schedule-for-kids-adults/